Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study on the efficacy and safety of olmesartan medoxomil and its combination with hydrochlorothiazide compared with an ACE inhibitor and its combination with a calcium channel blocker in patients with stage 2 hypertension

Next Previous
X
Search
Trial Profile

A study on the efficacy and safety of olmesartan medoxomil and its combination with hydrochlorothiazide compared with an ACE inhibitor and its combination with a calcium channel blocker in patients with stage 2 hypertension

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Feb 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olmesartan medoxomil (Primary) ; Olmesartan medoxomil/hydrochlorothiazide (Primary) ; Amlodipine; Amlodipine/benazepril; Benazepril; Hydrochlorothiazide
  • Indications Hypertension
  • Focus Pharmacodynamics
  • Sponsors Daiichi Sankyo Inc

    • Most Recent Events

    • 17 Jan 2012 Actual end date (Sep 2006) added as reported by ClinicalTrials.gov.
    • 05 May 2007 Status changed to completed; results data reported at ASH
    • 29 Oct 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top